BRITISH COLUMBIA, Canada, Sept. 9 /CNW/ -- InNexus Biotechnology Inc.,
(TSX: IXS.V, OTC Bulletin Board: IXSBF, http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, welcomes
David Warden to its Board of Directors.
